Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

被引：25

作者：

Rogoza, R. M. ^{[1
]}

Westra, T. A. ^{[2
,3
]}

Ferko, N. ^{[1
]}

Tamminga, J. J. ^{[4
]}

Drummond, M. F. ^{[5
,6
]}

Daemen, T. ^{[2
]}

Wilschut, J. C. ^{[2
]}

Postma, M. J. ^{[3
,7
]}

机构：

[1] i3 Innovus, Hlth Econ & Outcomes Res, Burlington, ON, Canada

[2] Univ Med Ctr Groningen, Dept Med Microbiol, Mol Virol Sect, NL-9700 RB Groningen, Netherlands

[3] Univ Groningen, Dept Pharm, Unit Pharmacoepidemiol & Pharmacoecon, Groningen, Netherlands

[4] GlaxoSmithKline, Hlth Outcomes, Zeist, Netherlands

[5] i3 Innovus, Uxbridge, Middx, England

[6] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England

[7] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands

来源：

VACCINE | 2009年 / 27卷 / 35期

关键词：

HPV; Cost-effectiveness; Cervical cancer; The Netherlands; PARTICLE VACCINE; HIGH-RISK; SUSTAINED EFFICACY; ECONOMIC-IMPACT; YOUNG-WOMEN; INFECTION; TYPE-16; HEALTH; SMEARS; STRATEGIES;

D O I：

10.1016/j.vaccine.2009.05.085

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cervical cancer is one of the most prevalent cancers among women worldwide. Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and 18 that cause cervical cancer is generally expected to significantly reduce the burden of cervical cancer disease. Here we estimate the costs, savings and health gains with the addition of HPV-16/18 vaccination to the already existing Dutch screening programme. In the base-case analysis, it was estimated that implementation of an HPV-16/18 vaccine would result in an incremental cost-effectiveness ratio (ICER) of (sic)22,700 per life-year gained (LYG). In sensitivity analysis, the robustness of our finding of favourable cost-effectiveness was established. The ICER appeared sensitive to the vaccine price, discount rate and duration of vaccine-induced protection. From our results, it validly follows that immunization of 12-year-old Dutch girls against HPV-16/18 infection is a cost-effective strategy for protecting against cervical cancer. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4776 / 4783

页数：8

共 70 条

[11]

BROWN D, 2007, INT C ANT AG CHEM IC

[12]

BROWN DR, 2009, J INFECT DIS 0223

[13] The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996 [J].

Bulk, S ;

van Kemenade, FJ ;

Rozendaal, L ;

Meijer, CJLM .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (04) :388-393

[14] Cost-effectiveness of human papillomavirus vaccination in the United States [J].

Chesson, Harrell W. ;

Ekwueme, Donatus U. ;

Saraiya, Mona ;

Markowitz, Lauri E. .

EMERGING INFECTIOUS DISEASES, 2008, 14 (02) :244-251

[15] Worldwide distribution of human papillomavirus types in cytologically normal women in the international Agency for Research on Cancer HPV prevalence surveys:: a pooled analysis [J].

Clifford, GM ;

Gallus, S ;

Herrero, R ;

Muñoz, N ;

Snijders, PJF ;

Vaccarella, S ;

Anh, PTH ;

Ferreccio, C ;

Hieu, NT ;

Matos, E ;

Molano, M ;

Rajkumar, R ;

Ronco, G ;

de Sanjosé, S ;

Shin, HR ;

Sukvirach, S ;

Thomas, JO ;

Tunsakul, S ;

Meijer, CJLM ;

Franceschi, S .

LANCET, 2005, 366 (9490) :991-998

[16] Carcinogenicity of human papillomaviruses [J].

Cogliano, V ;

Baan, R ;

Straif, K ;

Grosse, Y ;

Secretan, B ;

El Ghissassi, F .

LANCET ONCOLOGY, 2005, 6 (04) :204-204

[17] Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia [J].

Coupe, V. M. H. ;

Berkhof, J. ;

Verheijen, R. H. M. ;

Meijer, C. J. L. M. .

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2007, 114 (04) :416-424

[18] Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease [J].

Dasbach, Erik J. ;

Elbasha, Elarnin H. ;

Insinga, Ralph P. .

EPIDEMIOLOGIC REVIEWS, 2006, 28 :88-100

[19]

DAVID MP, 2009, GYNECOL ONCOL

[20] Model for assessing human papillomavirus vaccination strategies [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. ;

Insinga, Ralph P. .

EMERGING INFECTIOUS DISEASES, 2007, 13 (01) :28-41

← 1 2 3 4 5 6 7 →